The College of Nuclear Physicians of South Africa practice guidelines on peptide receptor radionuclide therapy in neuroendocrine tumours

Lawal, I. ; Louw, L. ; Warwick, James M. ; Nyakale, N. ; Steyn, R. ; Lengana, T. ; Ellmann, A. ; Kotze, T ; Vangu, M. ; Vorster, M. ; Sathekge, M. (2018)

CITATION: Lawal, I., et al. 2018. The College of Nuclear Physicians of South Africa Practice Guidelines on peptide receptor radionuclide therapy in neuroendocrine tumours. South African Journal of Surgery, 56(3):55-64, doi:10.17159/2078-5151/2018/v56n3a2775.

The original publication is available at http://www.scielo.org.za

Article

Background: Peptide receptor radionuclide therapy (PRRT) for metastatic or inoperable neuroendocrine tumours (NETs) is a systemic therapy which targets somatostatin receptors overexpressed by differentiated NETs for endoradiotherapy. This guideline has been compiled by the College of Nuclear Physicians of the Colleges of Medicine of South Africa, with endorsement by the South African Society of Nuclear Medicine and the Association of Nuclear Physicians to guide Nuclear Medicine Physicians in its application during the management of these patients. Recommendations: Patients with well- to moderately-differentiated NETs should be comprehensively worked-up to determine their suitability for PRRT. Treatment should be administered by a Nuclear Medicine Physician in a licensed, appropriately equipped and fully staffed facility. Patient monitoring is mandatory during and after each therapy cycle to identify and treat therapy-related adverse events. Patients should also be followed-up after completion of therapy cycles for monitoring of long-term toxicities and response assessment. Conclusion: PRRT is a safe and effective therapy option in patients with differentiated NETs. Its use in appropriate patients is associated with a survival benefit.

Please refer to this item in SUNScholar by using the following persistent URL: http://hdl.handle.net/10019.1/107581
This item appears in the following collections: